Pfizer Inc. (NYSE: PFE) announced that China’s National Medical Products Administration (NMPA) has officially approved a new indication for Hympavzi (marstacimab) — the world’s first non‑factor innovative therapy administered via a once‑weekly fixed‑dose subcutaneous injection — for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older (weighing ≥35 kg) with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors or hemophilia B (congenital factor IX deficiency) with factor IX inhibitors, further expanding its eligible patient population in China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | New indication approval |
| Product | Hympavzi (marstacimab) |
| Modality | Non‑factor therapy – once‑weekly fixed‑dose subcutaneous injection |
| Indication | Routine prophylaxis to prevent or reduce the frequency of bleeding episodes |
| Patient Population | Adults and pediatric patients aged ≥12 years (weight ≥35 kg) with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors |
| Approval Date | 6 Nov 2026 |
| Supporting Evidence | Global Phase III BASIS study |
| Impact | Further expands Hympavzi’s eligible patient population in China |
Drug Profile & Mechanism of Action
- Molecule: Marstacimab — a tissue factor pathway inhibitor (TFPI)‑targeting monoclonal antibody.
- Non‑Factor Mechanism: Rather than replacing the deficient clotting factor, Hympavzi rebalances hemostasis by inhibiting TFPI, restoring thrombin generation independently of factor VIII or IX — a mechanism that works regardless of inhibitor status.
- First‑in‑Class Administration: The world’s first non‑factor innovative therapy delivered as a once‑weekly, fixed‑dose subcutaneous injection, replacing frequent intravenous factor infusions with a simple, predictable regimen.
- Dual‑Disease Coverage: A single prophylactic agent now approved in China for both hemophilia A and hemophilia B with inhibitors, spanning the two major congenital deficiency phenotypes.
- Fixed Dosing: The fixed‑dose design removes weight‑based titration complexity for maintenance therapy, simplifying long‑term management for patients and treatment centers.
Clinical Evidence – Global Phase III BASIS Study
| Endpoint | Result |
|---|---|
| Study Design | Hemophilia A or B patients with inhibitors, previously on on‑demand treatment with bypassing agents, switched to routine prophylaxis with Hympavzi; 12‑month treatment period |
| Mean Annualized Bleeding Rate (ABR) – Treated Bleeds | 19.78 (prior on‑demand) → 1.39 (Hympavzi prophylaxis) |
| Relative Reduction | 93 % (ABR ratio: 0.07; 95 % CI: 0.042–0.118; two‑sided P<0.0001) |
| Quality of Life | Significant improvements in patient‑reported health‑related quality of life |
The global Phase III BASIS study formed the evidentiary basis for the new indication approval. In the inhibitor population — historically the most difficult‑to‑treat hemophilia cohort, reliant on bypassing agents for on‑demand bleed control — switching to once‑weekly Hympavzi prophylaxis reduced the mean ABR for treated bleeds by 93 % over 12 months, with statistically significant and clinically meaningful results accompanied by improved patient‑reported outcomes.
Market Impact & Outlook
- High‑Unmet‑Need Population: Patients with inhibitors neutralize conventional factor replacement therapy, leaving bypassing agents as the historical standard; Hympavzi introduces a prophylactic, non‑factor alternative that addresses the root limitation of factor‑based care.
- Transformative Regimen Simplicity: Once‑weekly fixed‑dose subcutaneous injection markedly lowers the treatment burden versus frequent intravenous infusions — a decisive advantage for adherence, home‑based care, and adolescent patients transitioning to self‑administration.
- Expanded China Footprint: The new indication broadens Hympavzi’s eligible patient population in China, adding the inhibitor‑positive hemophilia A and B communities aged ≥12 years (≥35 kg) to its label.
- Best‑in‑Class Signal: A 93 % reduction in treated‑bleed ABR with a 95 % CI upper bound of 0.118 and P<0.0001 in the BASIS study positions Hympavzi as a benchmark efficacy result in inhibitor‑patient prophylaxis.
- Beyond Bleed Rates: Significant health‑related quality‑of‑life improvements reinforce the value proposition for payers, clinicians, and patients — an increasingly important dimension in rare‑disease access negotiations.
- Watch Items: Commercial launch and treatment‑center rollout in China, reimbursement and access discussions, real‑world adherence under the weekly subcutaneous regimen, and potential pediatric population expansion below age 12.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, patient access, and clinical deployment of Hympavzi (marstacimab) in China following NMPA approval of the new indication. Actual results may differ due to risks including reimbursement and market‑access outcomes, launch execution, competitive dynamics in hemophilia prophylaxis, real‑world safety and effectiveness, and regulatory developments in additional markets.-Fineline Info & Tech
